Concept Medical Reports 88% 3‑Year cdTLR Freedom

Concept Medical presented preliminary 3‑year SIRONA trial data at the CX Symposium 2026 in London, comparing sirolimus‑coated MagicTouch PTA to paclitaxel‑coated balloons.
At 3 years, freedom from clinically driven target lesion revascularization was 88.2% vs 80.2% (HR 0.60, p=0.03), favoring the sirolimus arm.
All‑cause mortality (92.6% vs 92.6%) and major amputation rates (99.6% vs 99.6%) were comparable between groups, showing similar safety.
Dr. Manish Doshi highlighted the trial underscores long‑term durability of sirolimus‑coated balloons and supports global scaling of the technology.